<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101465400</journal-id>
<journal-id journal-id-type="pubmed-jr-id">34171</journal-id>
<journal-id journal-id-type="nlm-ta">Sci Signal</journal-id>
<journal-id journal-id-type="iso-abbrev">Sci Signal</journal-id>
<journal-title-group>
<journal-title>Science signaling</journal-title>
</journal-title-group>
<issn pub-type="ppub">1945-0877</issn>
<issn pub-type="epub">1937-9145</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28465421</article-id>
<article-id pub-id-type="pmc">5557344</article-id>
<article-id pub-id-type="doi">10.1126/scisignal.aai8133</article-id>
<article-id pub-id-type="manuscript">NIHMS877598</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Hyperactive locomotion in a <italic>Drosophila</italic> model is a functional readout for the synaptic abnormalities underlying fragile X syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kashima</surname>
<given-names>Risa</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN2">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Redmond</surname>
<given-names>Patrick L.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN2">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ghatpande</surname>
<given-names>Prajakta</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Roy</surname>
<given-names>Sougata</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kornberg</surname>
<given-names>Thomas B.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hanke</surname>
<given-names>Thomas</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Knapp</surname>
<given-names>Stefan</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lagna</surname>
<given-names>Giorgio</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hata</surname>
<given-names>Akiko</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN2">†</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA 94158, USA</aff>
<aff id="A2">
<label>2</label>Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA</aff>
<aff id="A3">
<label>3</label>Institute of Pharmaceutical Chemistry and Buchmann Institute for Life Sciences, Goethe University, Frankfurt, Germany</aff>
<aff id="A4">
<label>4</label>Department of Clinical Medicine, Structural Genomics Consortium, University of Oxford, Oxford OX3 7DQ, U.K</aff>
<author-notes>
<corresp id="FN1"><label>†</label>Corresponding author. <email>akiko.hata@ucsf.edu</email></corresp>
<fn fn-type="equal" id="FN2">
<label>*</label>
<p>These authors contributed equally to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>23</day>
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>02</day>
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<day>02</day>
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>15</day>
<month>8</month>
<year>2017</year>
</pub-date>
<volume>10</volume>
<issue>477</issue>
<elocation-id>eaai8133</elocation-id>
<abstract>
<p id="P1">Fragile X syndrome (FXS) is the most common cause of heritable intellectual disability and autism and affects ~1 in 4000 males and 1 in 8000 females. The discovery of effective treatments for FXS has been hampered by the lack of effective animal models and phenotypic readouts for drug screening. FXS ensues from the epigenetic silencing or loss-of-function mutation of the <italic>fragile X mental retardation 1</italic> (<italic>FMR1</italic>) gene, which encodes an RNA binding protein that associates with and represses the translation of target mRNAs. We previously found that the activation of LIM kinase 1 (LIMK1) downstream of augmented synthesis of bone morphogenetic protein (BMP) type 2 receptor (BMPR2) promotes aberrant synaptic development in mouse and <italic>Drosophila</italic> models of FXS and that these molecular and cellular markers were correlated in patients with FXS. We report that larval locomotion is augmented in a <italic>Drosophila</italic> FXS model. Genetic or pharmacological intervention on the BMPR2-LIMK pathway ameliorated the synaptic abnormality and locomotion phenotypes of FXS larvae, as well as hyperactivity in an FXS mouse model. Our study demonstrates that (i) the BMPR2-LIMK pathway is a promising therapeutic target for FXS and (ii) the locomotion phenotype of FXS larvae is a quantitative functional readout for the neuromorphological phenotype associated with FXS and is amenable to the screening novel FXS therapeutics.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>